Skip to main content
TipRanks
Go Ultimate75% OFF

Entera Bio (5DT) AI Stock Analysis

0 Followers
DE:5DT

Entera Bio

(Frankfurt:5DT)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low LeverageVery low leverage gives Entera substantial balance-sheet flexibility relative to its development-stage operations. The reported equity and asset base can support continued clinical investment and reduce near-term debt-service pressure, although the company still must convert capital into durable operating progress.
Negative Factors
Minimal Revenue and Persistent LossesEntera has not established recurring product revenue, and substantial operating losses continue despite the recent TTM net-income improvement. This leaves results dependent on development progress and non-operating items rather than a proven commercial engine, limiting earnings durability over the medium term.

Entera Bio (5DT) vs. iShares MSCI Germany ETF (EWG)

-75%-50%-25%0%25%50%75%DE:5DT+27.68%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 541.57M
Dividend Yield
―
Average Volume (3M)
794
Price to Earnings (P/E)
-8.0
Beta (1Y)
0.68
Revenue Growth
-100.00%
EPS Growth
-52.24%
Country
Germany
Employees
27
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Entera Bio Business Overview & Revenue Model

Company Description

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experi...

Entera Bio Risk Analysis

Entera Bio disclosed 2 risk factors in its most recent earnings report. Entera Bio reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk
1.Recently Issued Accounting PronouncementsQ2, 2026

Entera Bio Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:5DT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NRXPNRXP46Neutral$95.59M-2.95168.68%――67.07%
EQEQ42Neutral$106.20M-7.32-37.33%―-100.00%71.65%
PLRXPLRX42Neutral$43.21M-0.48-58.31%――49.00%
ATYRATYR33Underperform$14.97M-0.28-102.46%―-100.00%34.89%

* Healthcare Sector Average

Performance Comparison

0%100%200%DE:5DTATYRNRXPEQPLRXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:5DT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:5DTEntera Bio2.860.5825.44%
ATYRAtyr Pharma Inc.6.11-21.10-77.56%
NRXPNrx Pharmaceuticals, Inc.2.190.083.79%
EQEquillium1.290.2422.86%
PLRXPliant Therapeutics, Inc.0.70-0.95-57.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.